SEP
TGTX icon

Signature Equity Partners’s TG Therapeutics TGTX Stock Holding History

Signature Equity Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275 Hold
5
– – ﹤0.01% 1493
2026
Q1 		$166 Buy
+5
New +$149 ﹤0.01% 1498

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Signature Equity Partners's TGTX Position: Q2 2026 in Review

Signature Equity Partners held its TG Therapeutics (TGTX) position steady in Q2 2026 at 5 shares worth $275. The position accounts for ﹤0.01% of the portfolio, ranked #1493.

Signature Equity Partners first reported a position in TGTX in Q1 2026 and has held it in 2 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Signature Equity Partners held 5 shares of TG Therapeutics worth $275 as of Q2 2026.
  • Signature Equity Partners left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1493 holding.
  • Signature Equity Partners first reported a position in TG Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.